Mariner
CRSP icon

Mariner’s CRISPR Therapeutics CRSP Stock Holding History

Mariner’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$642K Sell
13,491
-3,418
-20% -$180K ﹤0.01% 2298
2025
Q4 		$886K Buy
16,909
+2,877
+21% +$172K ﹤0.01% 2030
2025
Q3 		$909K Buy
14,032
+2,086
+17% +$120K ﹤0.01% 1987
2025
Q2 		$581K Buy
+11,946
New +$462K ﹤0.01% 2210
2025
Q1 		– Sell
-5,765
Closed -$227K – 3470
2024
Q4 		$227K Sell
5,765
-746
-11% -$35.2K ﹤0.01% 2893
2024
Q3 		$306K Sell
6,511
-274
-4% -$13.9K ﹤0.01% 2553
2024
Q2 		$367K Sell
6,785
-1,413
-17% -$81.7K ﹤0.01% 2297
2024
Q1 		$559K Buy
8,198
+2,162
+36% +$155K ﹤0.01% 1943
2023
Q4 		$378K Sell
6,036
-1,454
-19% -$80.4K ﹤0.01% 2151
2023
Q3 		$340K Buy
7,490
+938
+14% +$48.4K ﹤0.01% 2048
2023
Q2 		$368K Buy
+6,552
New +$372K ﹤0.01% 1965
2022
Q4 		– Sell
-3,586
Closed -$234K – 2759
2022
Q3 		$234K Buy
+3,586
New +$260K ﹤0.01% 1948

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Mariner's CRSP Position: Q1 2026 in Review

Mariner reduced its CRISPR Therapeutics (CRSP) stake by 20% in Q1 2026, selling an estimated $180K and leaving 13,491 shares worth $642K. The position accounts for ﹤0.01% of the portfolio, ranked #2298.

Mariner first reported a position in CRSP in Q3 2022 and has held it in 12 quarters since. The position peaked at $909K in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Mariner held 13,491 shares of CRISPR Therapeutics worth $642K as of Q1 2026.
  • Mariner sold 3,418 CRISPR Therapeutics shares in Q1 2026, an estimated $180K.
  • CRISPR Therapeutics made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #2298 holding.
  • Mariner first reported a position in CRISPR Therapeutics in Q3 2022 and has held it in 12 quarters since.
  • Mariner's CRISPR Therapeutics position peaked at $909K in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.